『STEM-Talk』のカバーアート

STEM-Talk

STEM-Talk

著者： Dawn Kernagis and Ken Ford
無料で聴く

The most interesting people in the world of science and technologyFlorida Institute for Human and Machine Cognition 代替医療・補完医療 博物学 科学 自然・生態学 衛生・健康的な生活
エピソード
  • Episode 197: Scott Sherr discusses hyperbaric oxygen therapy, methylene blue, and more

    Episode 197: Scott Sherr discusses hyperbaric oxygen therapy, methylene blue, and more
    2026/07/15
    Today we have Dr. Scott Sherr, an internal medicine physician who specializes in Hyperbaric Oxygen Therapy. Scott is the director of Integrative Hyperbaric Medicine and Heath Optimization at Hyperbaric Medical Solutions. It is a division of Hyperbaric Medical Solutions, an independent, hyperbaric oxygen therapy provider that aims to educate people about the benefits of hyperbaric oxygen therapy via telemedicine consulting. He also is COO of Troscriptions, which provides physician-formulated products including popular methylene blue products. In today’s interview, Scott talks about how he uses Hyperbaric Oxygen Therapy (HBOT) to treat a number of health conditions. He also shares how he incorporates methylene blue into some of his treatment strategies and explains how HBOT is now being used as a complementary treatment for autoimmune diseases by helping reduce inflammation, improve blood flow and support immune function. Show notes: [00:03:29] Dawn tells Scott that she heard a story that Scott had his spine adjusted when he was just five minutes old. She asks Scott if he can share what happened. [00:04:15] Dawn mentions that Scott grew up in New York on Long Island and that as a child he spent a lot of time at his father’s chiropractic office. Dawn asks Scott about his father and his practice. [00:05:38] Ken notes that Scott was into sports as a kid and asks him to talk about his childhood and what he was like as a kid. [00:07:09] Dawn notes that after high school, Scott left New York for the West Coast, landing at UCLA. Dawn asks Scott to talk about what led him there. [00:08:00] Dawn explains that Scott initially started to major in biology but quickly changed majors. Scott explains why he changed majors. [00:08:41] Dawn asks Scott why he chose to attend the University of Maryland for medical school after graduating from UCLA. [00:09:26] Dawn asks Scott about the story of how he met his wife at the University of Maryland. [00:09:50] Dawn pivots back to Scott’s love of music, mentioning that Scott and three other medical school students at Maryland formed a band called The Airport Rocking Chairs. Scott describes how the band came together and how they performed at gigs around the Baltimore/D.C. area. [00:11:16] Ken asks Scott to talk about how his early ambition upon entering medical school was to find a way to bridge the gap between conventional and alternative/chiropractic medicine. [00:12:54] Ken explains that in Scott’s third year of medical school, he did rotations at the University Shock and Trauma Facility. Ken asks Scott to talk about why this was such an important experience for Scott. [00:14:32] Dawn explains that hyperbaric chambers are used to treat injuries like necrotizing fasciitis and severe wounds. Dawn asks Scott to talk about finding a hyperbaric chamber in the basement of the University Shock and Trauma Facility and how that led to his fascination with the potential for hyperbaric oxygen therapy. [00:15:51] Dawn asks Scott to talk about how his initial research on hyperbaric therapies led him to conclude that they were being vastly underutilized in conventional medicine. [00:16:31] Dawn mentions that people are likely familiar with hyperbaric oxygen therapy (HBOT) in terms of treating divers suffering from decompression sickness. She asks Scott to give a primer on the mechanisms by which HBOT affects the body and why it has potential to treat other conditions besides decompression sickness. [00:19:38] Ken asks Scott to talk more about other conditions, both acute and chronic, that HBOT might be helpful in treating. [00:22:51] Dawn asks about Scott’s experience as a hospitalist, which is an internal medicine physician who acts as a primary care physician in a hospital, and how this experience gave him a unique perspective on the strengths and limitations of modern medicine. [00:25:13] Ken asks Scott if it’s fair to say that his experience as a hospitalist was foundational in developing his understanding of patient care and healthspan. [00:26:51] Dawn explains that when Scott’s wife received a fellowship at Stanford University, Scott eventually left his career as a hospitalist to serve as the medical director for a hyperbaric medicine facility in the San Francisco Bay area. Dawn asks Scott to talk about how this experience deepened his understanding and expertise in hyperbaric oxygen therapy. [00:28:26] Ken asks Scott to talk about his relationship with Dominic D’Agostino, who was our recent guest on STEM-Talk episode 196, and who is very active in the field of hyperbaric oxygen therapy. [00:30:48] Dawn mentions that during Scott’s work as a hospitalist, he began to develop a more integrated approach to hyperbaric medicine, taking nutritional status, sleep patterns, mitochondrial function, and a number of other factors into consideration. Doing this work, Scott noticed that a number of patients would require weeks or months of preparation before beginning HBOT, ...
    続きを読む 一部表示
    1 時間 27 分
  • Episode 196: Dominic D’Agostino discusses advances in ketogenic metabolic therapy and hyperbaric oxygen therapy

    Episode 196: Dominic D’Agostino discusses advances in ketogenic metabolic therapy and hyperbaric oxygen therapy
    2026/06/11
    Today we have Dr. Dominic D’Agostino, who over the past 10 years has been a frequent guest on STEM-Talk. Today Dom joins us to give us an update on his recent research into ketogenic metabolic therapies, ketone supplements as well as hyperbaric oxygen therapy for traumatic brain injuries. Dom and his lab at the University of South Florida have published more than 20 papers since his last appearance on STEM-Talk in 2023. Dom is an Associate Professor in the Department of Molecular Pharmacology and Physiology at South Florida’s Morsani College of Medicine. Dom has a background in neuroscience, molecular pharmacology, nutrition and physiology. In addition to developing and testing metabolic-based therapies, Dom’s lab also investigates seizure disorders, brain cancer, neurodegenerative diseases and rare genetic-metabolic disorders. Show notes: [00:03:28] Dawn welcomes Dom back to the show and explaining that he has been quite busy since his last appearance, authoring or co-authoring more than 20 papers. Over the past several years, Dom has been helping to advance the science and application of ketogenic metabolic therapy (KMT) with colleagues at Moffitt Cancer Center, particularly focusing on using KMT to enhance immune-based therapies for certain types of cancers. Dawn asks Dom about this collaboration. [00:05:04] Dawn explains that ketogenic metabolic therapy is a dietary approach that focuses on a high-fat/low-carb diet to reduce glucose availability for cancer cells, potentially slowing their growth and improving treatment outcomes. It has been explored as a complimentary treatment for a variety of cancers including gliomas by shifting the metabolism of tumor cells away from glucose. Dawn asks Dom to explain what is involved in KMT. [00:06:58] Dawn clarifies that KMT requires less than 20-25 grams of carbohydrates per day, and that ketosis is a metabolic state in which the body switches from glucose metabolism to metabolizing fats in the form of ketones. Dawn goes on to explain that cancer cells typically consume glucose at a higher rate than normal cells. However, cancer cells are also very adaptable, and Dawn asks Dom to talk about this feature of cancer cells. [00:09:14] Ken explains that KMT has shown the most promise in treating high-grade gliomas, or brain cancers, such as glioblastoma, which is the most aggressive primary brain tumor in adults. Ken explains that Dom was part of a massive review titled “Clinical research framework proposal for ketogenic metabolic therapy in glioblastoma,” which proposed guidelines for the management of glioblastoma based on an understanding of cancer as a metabolic disease, particularly involving mitochondria. Ken asks Dom to talk about this review. [00:11:21] From a patient advocacy perspective, Ken notes that the review recommends that there should be an aggressive education campaign that can arm patients with knowledge about KMT and other novel therapies. Ken asks Dom to talk about that recommendation. [00:13:15] Ken asks about the process of cutting the review from upwards of 200 pages down to around 50 pages with 49 authors. [00:15:04] Dawn mentions that Dom was part of another paper in 2024 titled “Targeting the mitochondrial stem cell connection in cancer treatment – a hybrid orthomolecular protocol.” Dawn explains that this paper looked at the mitochondrial stem cell connection theory (MSCC), which argues that cancer originates from chronic oxidative phosphorylation insufficiency in stem cells. This insufficiency leads to the formation of cancer stem cells and abnormal energy metabolism ultimately resulting in malignancy. There were 16 research centers and organizations involved in this paper which introduced a hybrid orthomolecular protocol to target the mitochondrial stem-cell connection. Dawn asks Dom to give an overview of MSCC. [00:18:26] Dawn explains that in this paper Dom and his co-authors propose a protocol that would enhance oxidative phosphorylation and inhibit the primary fuels of cancer, glucose and glutamine. This would target both cancer stem cells and metastasis. Dawn asks Dom to explain why this concept is attracting so much interest as a potential therapeutic approach for cancer. [00:20:48] Dawn asks if Dom could discuss the orthomolecular protocol, which is an approach that focuses on preventing and treating diseases by correcting nutritional balances in the body. [00:24:41] Ken asks if the proposed dietary intervention in the orthomolecular approach is different from a standard or typical ketogenic diet. [00:26:48] Ken shifts the discussion to talk about ketone supplements, explaining that Dom recently published a paper titled “Divergent hepatic outcomes of chronic ketone supplementation.” Ken goes on to explain that ketone salts preserve liver health, while some ketone esters and precursors appear to drive inflammation and steatosis. There is a lot of interest in ketone supplementation because they substantially ...
    続きを読む 一部表示
    1 時間 11 分
  • Episode 195: Doug Cooke discusses NASA’s challenges in the space race to the Moon and Mars

    Episode 195: Doug Cooke discusses NASA’s challenges in the space race to the Moon and Mars
    2026/05/21
    Our guest today is Doug Cooke, an aerospace consultant who spent 38 years at NASA’s Johnson Space Center in Houston and NASA Headquarters in Washington, D.C. STEM-Talk host and IHMC founder Dr. Ken Ford, a former Associate Director of NASA’s Ames Research Center and Director of NASA’s Center of Excellence in Information Technology, interviewed Doug just four days after the astronauts of NASA’s Artemis II mission splashed down in the Pacific Ocean following a historic 10-day roundtrip from the Earth to the Moon. In today’s episode, Ken and Doug discuss the Artemis mission as well as NASA’s plans to return humans to the lunar surface by 2028. Doug also shares his concern that China could one day surpass America’s leadership role in human spaceflight. During his 38 years at NASA, Doug played critical roles in the Space Shuttle, International Space Station and Human Exploration spaceflight programs. During the last three years of his NASA career, he served as Associate Administrator of the Exploration Systems Mission Directorate, which oversees the development of systems critical to NASA’s plans for human exploration of the Moon and Mars, including the Artemis program. Show notes: [00:04:05] Ken opens our interview with Doug by talking about the Artemis II mission, which is the first crewed mission beyond low earth orbit since Apollo 17 in 1972. Harrison Schmidtt, who was on Apollo 17, was our guest on episode 4. Ken asks Doug for his key takeaways of the Artemis II mission, which set the record for a manned mission from Earth, traveling 252,756 miles into space and breaking Apollo 13’s record. [00:06:18] Ken explains that the Artemis missions signal a new age of space exploration as well as the beginning of a new space race between the U.S. and China. NASA aims to land humans on the Moon by 2028 while China expects to land humans on the moon in 2030. Ken has previously stated that he does not have confidence in NASA’s current mission architecture to achieve NASA’s stated goal of 2028, and asks Doug for his thoughts on the matter. [00:07:28] Ken asks if it is true that Yuri Gagarin, who become the first human to fly into space, is what initially sparked Doug’s interest in science and space. [00:08:54] Ken notes that Gagarin’s orbit around the earth inspired President Kennedy to vow that the United States would ramp up its space program and become the first nation to land a man on the moon. Ken mentions that he believes the Apollo 11 mission, which landed astronauts Neil Armstrong and Buzz Aldrin on the lunar surface, was one the greatest technological advances in world history. Ken asks Doug for his thoughts on the success of the Apollo program. [00:10:28] Ken mentions that Doug went to college at Texas A&M and majored in aerospace engineering. Kens asks Doug how he got a job at NASA after graduating. [00:12:21] Ken explains that Doug was instrumental in the development of the space shuttle and the International Space Station during his time at NASA. Doug talks about what it was like working on those projects at NASA. [00:15:16] Ken mentions that Doug also had an instrumental role in the Lunar Reconnaissance Orbiter (LRO), Lunar Crater Observation and Sensing Satellite (LCROSS), and the broader Exploration Technology Program. Ken points out that Doug became head of the exploration technology program in 1990 under then NASA Associate Administrator Mike Griffin, who was our guest on episodes 134 and 189. Ken asks Doug about meeting Mike. [00:16:17] Ken mentions that Mike Griffin and Lisa Porter were our guests on episode 189, where they voiced concerns about NASA’s current plans for a return to the moon. Ken goes on to mention that near the end of Doug’s career at NASA, he was the head of Exploration Systems Mission Directorate (ESMD), which is responsible for the development of systems critical to NASA’s plans for future exploration of the Moon and Mars. Ken asks Doug to talk about his role as head of the directorate and the work he did there. [00:18:55] Ken explains that Doug has written extensively on the issues with the Artemis mission architecture, most notably in a recent article for space news. Before jumping into the article, Ken asks Doug to talk about why it is important and also a national-security concern that we return to the moon before China. [00:21:12] Looping back to Doug’s op-ed in Space News, Ken notes that Doug stressed the need for NASA to develop a plan-B for the Artemis mission, with Doug and others noting that without a plan-B, the U.S. risks of losing the space race to the Moon. Doug has also gone on record to say that China has a far simpler, more direct, and more technically conservative plan than NASA. Ken asks Doug to elaborate on this. [00:22:37] Ken asks Doug to talk about the issues he and others have identified with NASA’s current proposed landing system. [00:26:14] Ken asks Doug to give a better understanding for the listeners of just ...
    続きを読む 一部表示
    59 分
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません